P. Sneddon, D. P. Westfall, J. S. Fedan (1982). Cotransmitters in the motor nerves of the guinea-pig
vas deferens: electrophysiological evidence. Science 218: 693–695.
S. M. Stahl, L. Palazidou (1986). The pharmacology of depression: studies of neurotransmitter
receptors lead the search for biochemical lesions and new drug therapies. Trends Pharmacol.
Sci. 7: 349–354.
R. K. Sunhara, C. W. Dessauer, A. G. Gilman (1996). Complexity and diversity of mammalian
adenylyl cyclases. Ann. Rev. Pharmcol. Toxicol. 36: 461.
S. Swillens, J. E. Dumont (1980). A unifying model of current concepts and data on adenyl
cyclase activation by β-adrenergic agonist. Life Sci. 27: 1013–1028.
J. R. Teerlink, B. M. Massie (1999). β-Adrenergic blocker mortality trials in congestive heart
failure. Am. J. Cardiol. 84: 94R.
P. A. van Zwieten, P. B. Timmermans (1979). The role of central α-adrenoceptors in the mode of
action of hypotensive drugs. Trends Pharmacol. Sci. 1: 39–41.
P. A. van Zwieten (1993). An overview of the pharmacodynamic and therapeutic potential of
combinedαandβ-adrenoceptor antagonists. Drugs 45: 509.
J. C. Venter, P. Horne, B. Eddy, R. Greguski, C. M. Fraser (1984). α 1 -Adrenergic receptor
structure.Mol. Pharmacol. 26: 196–205.
C. Weyer, J. F. Gauthier, E. Danforth (1999). Development of β-3-adrenoceptor agonists for the
treatment of obesity and diabetes. Diabetes Metab. 25: 11.
B. Xu (2001). The importance of beta-adrenergic receptors in immune regulation: a link between
neuroendocrine and immune system. Med. Hypotheses 56: 273–276.
H. Zhong, K. P. Minneman (1999). Alpha-1-adrenoceptor subtypes. Eur. J. Pharmacol. 375: 26.
Dopamine and Dopaminergic Receptors
R. M. Bilder (1997). Neurocognitive impairment in schizophrenia and how it affects treatment
options.Can. J. Psychiatry 42: 255.
P. B. Bradley, S. H. Hirsch (1986). The Psychopharmacology and Treatment of Schizophrenia.
New York: Oxford University Press.
T. S. Braver, D. M. Barch, J. D. Cohen (1999). Cognition and control in schizophrenia: a com-
putational model of dopamine and prefrontal function. Biol. Psychiatry 46: 312.
A. Breier, P. H. Berg (1999). The psychosis of schizophrenia: prevalence, response to atypical
antipsychotics, and prediction of outcome. Biol. Psychiatry 46: 361.
A. Carlsson, N. Waters, M. L. Carlsson (1999). Neurotransmitter interactions in schizophrenia:
therapeutic implications. Biol. Psychiatry 46: 1388.
M. L. Carlsson, A. Carlsson, M. Nilsson (2004). Schizophrenia: from dopamine to glutamate and
back.Curr. Med. Chem. 11: 267–277.
I. Creese, D. R. Sibley, M. W. Hamblin, S. E. Leff (1983). The classification of dopamine recep-
tors: relationship to radioligand binding. Annu.Rev. Neurosci. 6: 43–71.
B. Cusack, A. Nelson, E. Richelson (1994). Binding of antidepressants to human brain receptors:
focus on newer generation compounds. Psychopharmacol. 114: 559.
L. L. Demchyshyn, B. F. O’Dowd, S. R. George (2003). Structure of mammalian D1 and D5
dopamine receptors and their function and regulation in cells. Neurol. Dis. Ther. 56 : 45–76.
R. S. Duman, G. Heninger, E. Nestler (1997). A molecular and cellular theory of depression.
Arch. Gen. Psychiatry 54: 597.
S. B. Dunnett, A. Bjorklund (1999). Prospects for new restorative and neuroprotective treatments
in Parkinson’s disease. Nature, 399 : A32.
R. H. Edwards (1993). Neural degeneration and the transport of neurotransmitters. Ann. Neurol.
34 : 638.
302 MEDICINAL CHEMISTRY